BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24161620)

  • 21. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
    Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
    Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker.
    Misu T; Takano R; Fujihara K; Takahashi T; Sato S; Itoyama Y
    J Neurol Neurosurg Psychiatry; 2009 May; 80(5):575-7. PubMed ID: 19372295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
    J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
    Kuroda H; Fujihara K; Takano R; Takai Y; Takahashi T; Misu T; Nakashima I; Sato S; Itoyama Y; Aoki M
    J Neuroimmunol; 2013 Jan; 254(1-2):178-82. PubMed ID: 23017732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis.
    Wu A; Zhong X; Wang H; Xu W; Cheng C; Dai Y; Bao J; Qiu W; Lu Z; Hu X
    Can J Neurol Sci; 2012 Nov; 39(6):813-20. PubMed ID: 23041403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
    Constantinescu R; Romer M; Oakes D; Rosengren L; Kieburtz K
    Parkinsonism Relat Disord; 2009 Mar; 15(3):245-8. PubMed ID: 19056308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse.
    Wang H; Wang K; Zhong X; Qiu W; Dai Y; Wu A; Hu X
    J Clin Immunol; 2012 Oct; 32(5):1007-11. PubMed ID: 22644841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
    Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
    Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica.
    Liu C; Xu Y; Cui L; Wang J; Peng B; Zhong L; Chen X
    J Clin Neurosci; 2013 Feb; 20(2):278-80. PubMed ID: 23164828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse.
    Wang H; Wang K; Zhong X; Dai Y; Wu A; Li Y; Hu X
    J Neuroimmunol; 2012 Feb; 243(1-2):52-5. PubMed ID: 22177277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-d-aspartate receptor encephalitis.
    Li J; Gu Y; An H; Zhou Z; Zheng D; Wang Z; Wen Z; Shen HY; Wang Q; Wang H
    Brain Behav; 2019 Aug; 9(8):e01354. PubMed ID: 31313506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder.
    Liu B; Zhong X; Lu Z; Qiu W; Hu X; Wang H
    Neuroimmunomodulation; 2018; 25(4):185-192. PubMed ID: 30423585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica.
    Tortorella C; Ruggieri M; Di Monte E; Ceci E; Iaffaldano P; Direnzo V; Mastrapasqua M; Frigeri A; Amato MP; Hakiki B; Ghezzi A; Lugaresi A; De Luca G; Patti F; D'Amico E; Sola P; Simone AM; Svelto M; Livrea P; Trojano M
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1355-9. PubMed ID: 21622936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigation of B-cell activating factor in serum and cerebrospinal fluid of patients with neuromyelitis optical].
    Yang F; Huang D; Wu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Mar; 35(3):380-3. PubMed ID: 25818784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis.
    Rossi D; Volanti P; Brambilla L; Colletti T; Spataro R; La Bella V
    J Neurol; 2018 Mar; 265(3):510-521. PubMed ID: 29322259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
    J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
    Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
    Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.